Cue Biopharma, Inc. (CUE) 

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Show less

Over the last 12 months, insiders at Cue Biopharma, Inc. have bought $30,900 and sold $0 worth of Cue Biopharma, Inc. stock.

On average, over the past 5 years, insiders at Cue Biopharma, Inc. have bought $962,605 and sold $810,900 worth of stock each year.

Highest buying activity among insiders over the last 12 months: PASSERI DANIEL R (CHIEF EXECUTIVE OFFICER) — $30,900.

The last purchase of 30,000 shares for transaction amount of $30,900 was made by PASSERI DANIEL R (CHIEF EXECUTIVE OFFICER) on 2024‑12‑16.